HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells

Head and Neck

Volumn 36, Issue 11, 2014, Pages 1547-1554

  Hah, J Hun ^a,b   Zhao, Mei ^a   Pickering, Curtis R ^a   Frederick, Mitchell J ^a   Andrews, Genevieve A ^a,c   Jasser, Samar A ^a   Fooshee, David R ^a,d   Milas, Zvonimir L ^a,e   Galer, Chad ^a,f   Sano, Daisuke ^a,g   William, William N ^a   Kim, Edward ^a   Heymach, John ^a   Byers, Lauren A ^a   Papadimitrakopoulou, Vali ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Seoul National University Hospital   (South Korea)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e M D ANDERSON CANCER CENTER ORLANDO   (United States)

^f INDIANA UNIVERSITY   (United States)

^g YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

epidermal growth factor receptor; erlotinib; head and neck squamous cell carcinoma; HRAS; resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; K RAS PROTEIN; RAS PROTEIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; HRAS PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN P21; QUINAZOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; GENE CONSTRUCT; GENE MUTATION; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA CELL; SQUAMOUS CELL CARCINOMA CELL LINE; WILD TYPE; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HEAD AND NECK NEOPLASMS; HUMAN; MOLECULARLY TARGETED THERAPY; MUTATION; PROCEDURES; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; ERLOTINIB HYDROCHLORIDE; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS P21(RAS); QUINAZOLINES; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84939257771     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23499     Document Type: Article

References (21)

1. Frederick MJ, VanMeter AJ, Gadhikar MA, et al., Phosphoproteomic analysis of signaling pathways in head and neck squamous cell carcinoma patient samples. Am J Pathol 2011; 178: 548-571.
2. Cohen EE, Halpern AB, Kasza K, Kocherginsky M, Williams R, Vokes EE,. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2009; 45: e155-e160.
3. Stewart JS, Cohen EE, Licitra L, et al., Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 2009; 27: 1864-1871.
4. William WN Jr, Weber RS, Lee JJ, et al., Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: objective responses and clinical outcomes. J Clin Oncol 2011; 29:(suppl; abstr 5520).
5. Scaltriti M, Baselga J,. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272.
6. Zhao M, Sano D, Pickering CR, et al., Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011; 17: 7248-7264.
7. Sano D, Fooshee DR, Zhao M, et al., Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model. Head Neck 2011; 33: 349-358.
8. Rodriguez-Viciana P, Warne PH, Dhand R, et al., Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994; 370: 527-532.
9. De Luca A, Maiello MR, D'Alessio A, Pergameno M, Normanno N,. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012; 16 Suppl 2: S17-S27.
10. Pao W, Wang TY, Riely GJ, et al., KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
11. Lièvre A, Bachet JB, Boige V, et al., KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
12. Lea IA, Jackson MA, Li X, Bailey S, Peddada SD, Dunnick JK,. Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns. Carcinogenesis 2007; 28: 1851-1858.
13. Sheu JJ, Hua CH, Wan L, et al., Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. Cancer Res 2009; 69: 2568-2576.
14. Agrawal N, Frederick MJ, Pickering CR, et al., Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-1157.
15. Anderson JA, Irish JC, Ngan BY,. Prevalence of RAS oncogene mutation in head and neck carcinomas. J Otolaryngol 1992; 21: 321-326.
16. Anderson JA, Irish JC, McLachlin CM, Ngan BY,. H-ras oncogene mutation and human papillomavirus infection in oral carcinomas. Arch Otolaryngol Head Neck Surg 1994; 120: 755-760.
17. Forbes SA, Bhamra G, Bamford S, et al., The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet 2008;chapter 10:unit 10.11.
18. Luwor RB, Lu Y, Li X, Liang K, Fan Z,. Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. Cancer Lett 2011; 306: 85-91.
19. Janmaat ML, Kruyt FA, Rodriguez JA, Giaccone G,. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003; 9: 2316-2326.
20. Normanno N, De Luca A, Maiello MR, et al., The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2006; 207: 420-427.
21. Yamatodani T, Ekblad L, Kjellén E, Johnsson A, Mineta H, Wennerberg J,. Epidermal growth factor receptor status and persistent activation of Akt and p44/42 MAPK pathways correlate with the effect of cetuximab in head and neck and colon cancer cell lines. J Cancer Res Clin Oncol 2009; 135: 395-402.